[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"HepQuant, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":81},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100629372","validation-of-different-methods-for-hepquant-duo-blood-sample-collection-100629372",false,"NCT07473817","Validation of Different Methods for HepQuant DuO® Blood Sample Collection","Inclusion Criteria:\n\n* adult healthy participant with no major comorbidities and lean body mass (BMI 18-25.5)\n* adult participant with all etiologies of parenchymal chronic liver disease or PBC or PSC with F2-F3 fibrosis or cirrhosis.\n\nExclusion Criteria:\n\n* under the age of 18\n* pregnancy\n* Unable to absorb orally administered cholate (examples could include underlying severe gastroparesis or having undergone extensive small bowel resection, conditions or post-operative state that could impair the absorption of the orally administered d4-cholate)\n* NPO (nothing through the mouth) status or those who are unable to ingest a thin liquid by mouth\n* for patients with cirrhosis, any hospital admission within 3 months of enrollment in the study.",true,"ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","This is a study to see the agreement of blood samples collected through different means and tube types for the HepQuant DuO Test. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data from patients living with chronic liver disease and healthy adult volunteers. The study has up to 2 study visits at an outpatient clinic and can take up to 4 weeks for a participant to complete study. At these visits, participants will undergo a HepQuant DuO test and other standard lab tests. In addition, the study team will ask about a participant's experience with different blood sampling methods.",[24,25],"Healthy Adult Participants","Liver Disease Chronic","NOT_YET_RECRUITING","2026-03-11",{"date":29,"type":30},"2026-03-16","ACTUAL",{"date":32,"type":20},"2026-04-20",{"date":34,"type":20},"2027-04-20",{"name":36,"class":37},"HepQuant, LLC","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100593645","cholate-clearance-in-fontan-and-heart-failure-100593645","NCT07009132","Cholate Clearance in Fontan and Heart Failure","Hepatic Perfusion and Liver Health as Assessed by Dual Cholate Clearance Assay in Fontan-associated Liver Disease (FALD)","Inclusion Criteria:\n\n* Fontan: Adult Fontan patients ≥ 18 years of age who have undergone right heart catheterization within the past 1 year.\n* RHF Controls: non-Fontan adults with two ventricle anatomy with systemic left ventricle, CVP estimate ≥ 8 mmHg and left ventricle (LV) function ≥ 50% by echocardiogram performed within the past 1 year. Can include those with congenital heart disease- repaired or unrepaired.\n* Normal Controls: non-Fontan adults with normal cardiac anatomy, normal biventricular function, \\\u003C moderate tricuspid regurgitation and CVP estimate \\\u003C 5 mmHg by echocardiogram performed within the past 1 year.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Unable to comprehend and\u002For give informed consent\n* Sensitivity to human serum albumin, or its preparations\n* Participants with extensive resection of large segments of the small intestine (short gut) or severe gastroparesis\n* Participants on non-selective beta blockers, angiotensin converting-enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), ursodeoxycholic acid, cholic acid, or other bile acids who are unwilling or unable to delay taking their normal dose the morning of their dual cholate clearance testing.\n* Participants on dietary supplements, bile acid sequestrants, GLP-1 agonists, narcotics, and other medications affecting gastric emptying or intestinal absorption who are unwilling or unable to delay taking or withhold as outlined in the instructions on deviating from the SHUNT test.\n* Contraindication to cardiac MRI\n* For RHF and normal controls: diabetes, chronic liver disease, \\>moderate alcohol use, BMI \\>30, oxygen-dependent, pulmonary hypertension22 on therapy, known porto-pulmonary hypertension",{"count":46,"type":20},75,"The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease (FALD).\n\nThis study aims to understand the role impaired blood flow to the liver plays in liver function in Fontan patients compared to patients with right heart failure and healthy controls. The study will also determine whether cholate clearance is a good measure to use in this population, and whether it will be able to predict clinical outcomes.\n\nParticipants will undergo a HepQuant dual cholate clearance assay and a cardiac magnetic resonance imaging (MRI) at the beginning of the study, and then data on health status will be collected for 5 years.",[49,50],"Fontan","Right Heart Failure","RECRUITING","2025-09-09",{"date":54,"type":30},"2025-09-15",{"date":56,"type":30},"2025-08-04",{"date":58,"type":20},"2031-12",{"name":36,"class":37},1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":60},"100597596","investigating-hepquant-duo-test-as-a-biomarker-in-alcohol-related-liver-disease-100597596","NCT07060547","Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease","Inclusion Criteria:\n\n* adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.\n\nadult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).\n\nExclusion Criteria:\n\n* Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.\n* patients with solid organ malignancy.\n* patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease\n* pregnancy\n* under the age of 18",{"count":68,"type":20},40,"This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.",[71,72],"Alcoholic Hepatitis","Alcohol-related Liver Disease","2025-07-01",{"date":75,"type":30},"2025-07-11",{"date":77,"type":30},"2025-06-10",{"date":79,"type":20},"2032-03",{"name":36,"class":37},""]